Tools and Instruments
Enhance Your Platform With StimulusBio Inside
Cell therapy customers no longer evaluate tools on throughput and automation alone. Activation quality, signal context, and reproducibility now influence purchasing decisions, even for platforms not sold as biological reagents. That shift creates both a risk and an opportunity.
StimulusBio Inside is an enabling biological interface, built on sbPCI™ technology, that embeds defined immune signaling directly into existing tools and systems. Manufacturers add biological differentiation without rebuilding core hardware, consumables, or automation.
From Hardware Execution to Biological Control
Many tools excel at handling cells but leave signaling decisions to external reagents or customer workarounds. That gap limits differentiation and shifts performance risk onto the customer.
StimulusBio Inside closes that gap by incorporating defined, controllable immune signaling directly into the platform offering. The system not only runs reliably, it helps guide cell behavior in an intentional, reproducible way. Three things change:
- Platform use connects more directly to biological outcomes
- Customer dependence on third-party activation reagents decreases
- Your value proposition extends beyond throughput and automation
A Biological Layer That Integrates Into What You Already Build
StimulusBio technology is a modular, non-genetic interface designed to fit into existing systems, not replace them. Integration formats are matched to partner needs: consumable components, embedded biological modules, or co-developed formats aligned to existing workflows.
Because signal presentation is programmable rather than fixed, the same integration supports multiple customer use cases without multiplying SKUs or fragmenting the product line.
Deep Biology Expertise, Without the R&D Overhead
Building in-house biological activation expertise is slow and expensive. Customers increasingly expect platforms to perform biologically, not just mechanically, and closing that gap internally can take years.
StimulusBio Inside lets manufacturers leverage deep immune signaling expertise as a partnership, not an acquisition. StimulusBio owns the biological design layer. Partners retain ownership of the system, the customer relationship, and the go-to-market strategy. The result:
- Faster path to biologically differentiated products
- Lower risk than building proprietary activation technology
- Clear division of responsibility between partners
Serve More Customer Programs Without Fragmenting Your Platform
Customers frequently ask tool manufacturers to support different cell types, phenotypes, or therapeutic modalities. That pressure strains standardized platforms and can push manufacturers toward costly bespoke variants.
StimulusBio technologies support screening-driven configuration, so biological signaling can adapt to different applications while the core system stays intact. One platform architecture. Multiple biological contexts.
Built to Translate Alongside Your Customers
Tools that perform well in early research but fail to carry forward into manufacturing lose long-term relevance. Translation readiness is a competitive concern, not just a technical one.
StimulusBio Inside supports bead-free formats, defined signaling, and workflows compatible with downstream scale-up. Partner platforms stay relevant as customer programs mature from discovery through IND-enabling work and into process development.
The Technology Foundation: sbPCI™
StimulusBio Inside runs on sbPCI™, StimulusBio’s programmable cell-surface interface technology. sbPCI controls how bioactive signals are presented at the cell surface, including identity, composition, and spatial context, without genetic modification of the presenting system.
That foundation is what makes sbPCI translate into partner systems: it maintains biological rigor while staying flexible enough to configure across different integration formats and customer applications.